Cross-Sector entity
Revolution Medicines is most often covered alongside Avance Nerve Graft, which appears in 3 of these 5 stories. Across a 108-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 3. markets accounts for 2 of the 5 tracked stories, while 3 other categories carry the remainder.
5 verified stories tracked
Last mentioned: Jul 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Revolution Medicines is most often covered alongside Avance Nerve Graft, which appears in 3 of these 5 stories. Across a 108-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 3. markets accounts for 2 of the 5 tracked stories, while 3 other categories carry the remainder. 0% of these stories carry negative sentiment. The tracked stories average 2 original sources each. We currently track 5 Cross-Sector stories that mention Revolution Medicines, published between March 22, 2026 and July 7, 2026.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Revolution Medicines. Shared-story counts are live from our verified record — not editorial picks.
Moderna flu vaccine PDUFA date
FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
Axsome full-year 2025 results
Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.
Revolution Medicines mid-2025 data readout
RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.
A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Source: The Motley Fool · Adria Cimino
DAFNA Capital Management reduced its position in Axogen by approximately 265,456 shares during the fourth quarter of 2025, a move valued at $6.53 million. Despite the trim, the hedge fund maintains a significant $15.6 million stake in the nerve-repair specialist, which has seen its stock price climb 71% over the past year.
DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, following a period of significant outperformance. Despite the trim, Axogen remains a core holding for the fund as the medical device maker continues to capitalize on its 20% revenue growth and dominant position in the peripheral nerve repair market.
Source: fool.com · Jonathan Ponciano (us)
